Novo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs for diabetes patients in the US through a text messaging pilot.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh